Results 41 to 50 of about 27,256 (249)

Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes [PDF]

, 2012
Background Despite the number of medications for type 2 diabetes, many people with the condition do not achieve good glycaemic control. Some existing glucose-lowering agents have adverse effects such as weight gain or hypoglycaemia. Type 2 diabetes tends
Clar, C., Court, Rachel A., Gill, J. A. (James Alexander), Waugh, Norman   +3 more
core   +1 more source

Efficacy and Safety of Sitagliptin for the Treatment of New-Onset Diabetes after Renal Transplantation

International Journal of Endocrinology, 2014
New-onset diabetes after transplantation (NODAT) is a common comorbidity after renal transplantation. Though metformin is the first-line agent for the treatment of type 2 diabetes, in renal transplant recipients, metformin is frequently avoided due to ...
Brian P. Boerner, Clifford D. Miles, Vijay Shivaswamy   +2 more
doaj   +1 more source

Sitagliptin 100 mg vs glimepiride 1–3 mg as an add-on to insulin and metformin in type 2 diabetes (SWIM)

Endocrine Connections, 2017
Objective: To compare the effect of sitagliptin (100 mg) vs glimepiride (1–3 mg) as add-on therapy in Indian type 2 diabetes (T2DM) patients on treatment with insulin and metformin (SWIM study).
Jothydev Kesavadev, Pradeep Babu Sadasivan Pillai, Arun Shankar, Gopika Krishnan, Sunitha Jothydev   +4 more
doaj   +1 more source

A randomized triple-blind controlled clinical trial evaluation of sitagliptin in the treatment of patients with non-alcoholic fatty liver diseases without diabetes

Frontiers in Medicine, 2022
The current study aimed to evaluate the efficacy of sitagliptin vs. placebo in treating non-alcoholic fatty liver disease (NAFLD). In a triple-blind randomized clinical trial, we assigned 120 eligible subjects with NAFLD to receive daily dosing of 50 mg ...
Azam Doustmohammadian, Ahmad Nezhadisalami, Fahimeh Safarnezhad Tameshke, Nima Motamed, Mansooreh Maadi, Mohammad Farahmand, Masoudreza Sohrabi, Cain C. T. Clark, Hossein Ajdarkosh, Amir Hossein Faraji, Mehdi Nikkhah, Elham Sobhrakhshankhah, Ramin Ebrahimi, Farhad Zamani   +13 more
doaj   +1 more source

Modeling Sitagliptin Effect on Dipeptidyl Peptidase 4 (DPP4) Activity in Adults with Hematological Malignancies After Umbilical Cord Blood (UCB) Hematopoietic Cell Transplant (HCT) [PDF]

, 2014
Background and Objectives— Dipeptidyl peptidase-4 (DPP4) inhibition is a potential strategy to increase the engraftment rate of hematopoietic stem/progenitor cells.
Bies, Robert R., Broxmeyer, Hal E., Chitnis, Shripad D., Farag, Sherif S., Messina-Graham, Steven, Strother, Robert M., Vélez de Mendizábal, Nieves   +6 more
core   +1 more source

Sitagliptin affects gastric cancer cells proliferation by suppressing Melanoma‐associated antigen‐A3 expression through Yes‐associated protein inactivation

Cancer Medicine, 2020
Sitagliptin is an emerging oral hypoglycemic agent that inhibits the development of a wide variety of tumors. Current researches indicate that the abnormal activation of Yes‐associated protein (YAP) promotes the proliferation and poor prognosis of ...
Qi Wang, Pan Lu, Tao Wang, Qianqian Zheng, Yan Li, Sean X. Leng, Xin Meng, Biao Wang, Jisheng Xie, Haiyan Zhang   +9 more
doaj   +1 more source

Effect of a dipeptidyl peptidase-IV inhibitor, des-fluoro-sitagliptin, on neointimal formation after balloon injury in rats. [PDF]

PLoS ONE, 2012
BackgroundRecently, it has been suggested that enhancement of incretin effect improves cardiac function. We investigated the effect of a DPP-IV inhibitor, des-fluoro-sitagliptin, in reducing occurrence of restenosis in carotid artery in response to ...
Soo Lim, Sung Hee Choi, Hayley Shin, Bong Jun Cho, Ho Seon Park, Byung Yong Ahn, Seon Mee Kang, Ji Won Yoon, Hak Chul Jang, Young-Bum Kim, Kyong Soo Park   +10 more
doaj   +1 more source

Circulating MicroRNAs in Elderly Type 2 Diabetic Patients [PDF]

, 2018
The circulating microRNAs (miRNAs) associated with type 2 diabetes (T2D) in elderly patients are still being defined. To identify novel miRNA biomarker candidates for monitoring responses to sitagliptin in such patients, we prospectively studied 40 T2D ...
Abballe, Luana, Besharat, Zein Mersini, Borgiani, Paola, Catanzaro, Giuseppina, Chiacchiarini, Martina, Dotta, Francesco, Ferretti, Elisabetta, Po, Agnese, Sabato, Claudia, Tesauro, Manfredi, Vacca, Alessandra   +10 more
core   +3 more sources

Asymmetric synthesis of γ-chloro-α,β-diamino- and β,γ-aziridino-α-aminoacylpyrrolidines and -piperidines via stereoselective Mannich-type additions of N-(diphenylmethylene)glycinamides across α-chloro-N-sulfinylimines [PDF]

, 2012
The asymmetric synthesis of new chiral gamma-chloro-alpha,beta-diaminocarboxylamide derivatives by highly diastereoselective Mannich-type reactions of N-(diphenylmethylene) glycinamides across chiral alpha-chloro-N-p-toluenesulfinylaldimines was ...
Augustyns, Koen, Callebaut, Gert, De Kimpe, Norbert, Mangelinckx, Sven, Tornroos, Karl W, Van der Veken, Pieter   +5 more
core   +3 more sources

Dipeptidyl-Peptidase 4 Inhibitor Sitagliptin Ameliorates Hepatic Insulin Resistance by Modulating Inflammation and Autophagy in ob/ob Mice

International Journal of Endocrinology, 2018
Obesity and type 2 diabetes are the most common metabolic diseases globally. They are associated with inflammation, oxidative stress, autophagy, and insulin resistance.
Wenbin Zheng, Jing Zhou, Shasha Song, Wen Kong, Wenfang Xia, Lulu Chen, Tianshu Zeng   +6 more
doaj   +1 more source